Glutamate for Metabolic Intervention in Coronary Surgery II
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.
Also called NCT02592824
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 321 participants
- Sponsor
- Registry
-
NCT02592824
-
- Other papers using this trial's data
- Effect of glutamate infusion on NT-proBNP after coronary artery bypass grafting in high-risk patients (GLUTAMICS II): A randomized controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Sweden
- Registry status
- Completed
Technical summary
Registry record NCT02592824. Randomized; quadruple masking; primary purpose prevention. Start 2015-11-15 (actual); primary completion 2020-10-30 (actual). Results posted on 2023-12-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Glutamate for Metabolic Intervention in Coronary Surgery II
- Acronym
- GLUTAMICSII
- Condition
- Coronary Artery Bypass Surgery
- Condition
- Postoperative Complications
- Condition
- Heart Failure
- Intervention (Drug)
- glutamate infusion
- Intervention (Drug)
- saline infusion
- Lead sponsor
- University Hospital, Linkoeping
- Collaborator
- Region Örebro County
- Collaborator
- University Hospital, Umeå
- Collaborator
- Sahlgrenska University Hospital
Record details
- Record id
cardio:ct-nct02592824- Content hash
ceadeba6c8aef3ccfb8abd85a24a0de47844281e04527e14040ba92ccf76ab70